Skip to main content
ORASURE TECHNOLOGIES INC logo

ORASURE TECHNOLOGIES INC — Investor Relations & Filings

Ticker · OSUR ISIN · US68554V1089 LEI · 529900GNNJPNM4XHXQ77 US Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2023-05-12 Regulatory Filings
Country US United States of America
Listing US OSUR

About ORASURE TECHNOLOGIES INC

https://www.orasure.com/

OraSure Technologies, Inc. develops, manufactures, and distributes diagnostic products and sample collection tools. The company specializes in non-invasive technologies, particularly oral fluid-based solutions, to decentralize diagnostics and improve healthcare access. Its portfolio includes point-of-care and over-the-counter rapid tests for infectious diseases such as HIV and COVID-19. A notable achievement is the development of the first over-the-counter at-home HIV test. Through its subsidiaries, OraSure also provides sample management solutions for the collection of biological samples used in genomic, metabolomic, and microbiome research, serving healthcare providers, researchers, and consumers.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on amendments to the company's bylaws related to proxy rules and does not contain financial statements or detailed financial data. It includes a description of the amendments and references the filing of the amended bylaws as an exhibit. The document is not an annual or quarterly report, earnings release, or any detailed financial report. It is a regulatory filing announcing a corporate governance change. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is 4647 characters, which is consistent with a typical 8-K filing. Confidence is high due to the clear identification of the form and content.
2023-05-12 English
10-Q
Interim / Quarterly Report Q1 2023
2023-05-10 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 10, 2023, reporting the company's quarterly financial results for the quarter ended March 31, 2023. It includes a press release announcing consolidated financial results and mentions a webcast conference call with management discussing these results. The document is 4390 characters long, which is relatively short and primarily serves as a current report to announce financial results and related events. It does not contain the full financial statements or detailed analysis typical of an Interim/Quarterly Report (IR), but rather an initial announcement of quarterly financial results. Therefore, this document fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly/periodical financial results with key highlights only.
2023-05-10 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a Notice of Exempt Solicitation submitted pursuant to Rule 14a-6(g)(1) under the Securities Exchange Act of 1934. It is a voluntary submission by Nia Impact Capital urging shareholders to vote FOR a specific shareholder proposal at the OraSure Technologies Annual Meeting. The content focuses on climate-related shareholder proposal details, rationale, and supporting arguments, but it is not a formal proxy statement or a report itself. It is a solicitation communication related to a shareholder vote, not the proxy statement or voting results. The document is not an Annual Report, Earnings Release, or any financial report. It is also not a Proxy Solicitation & Information Statement (PSI) because it is an exempt solicitation by a third party, not the company. Given the nature of the document as a solicitation notice under Rule 14a-6, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other categories.
2023-04-27 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a Schedule 14A filing, which is a Proxy Statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes information about the upcoming Annual Meeting, voting items, board recommendations, and instructions for shareholders to vote. The document is not the proxy statement itself but appears to be definitive additional materials related to the proxy statement. Given the content and the SEC form type DEFA14A, this filing corresponds to Remuneration Information or Proxy Solicitation & Information Statement. Since it includes voting on executive compensation and other shareholder proposals, it fits best under Proxy Solicitation & Information Statement (PSI). The document length is under 5,000 characters and it is a definitive additional material, not the full proxy statement, but the best matching category is PSI rather than DEF 14A because it is additional materials related to proxy solicitation.
2023-04-14 English
ARS
Annual Report
2023-04-14 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.